The FDA has granted Breakthrough Therapy designation to JNJ-6372 (Janssen) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results